EA002020B1 - Способ генерации противовирусного иммунного ответа у человека или животного - Google Patents
Способ генерации противовирусного иммунного ответа у человека или животного Download PDFInfo
- Publication number
- EA002020B1 EA002020B1 EA199800746A EA199800746A EA002020B1 EA 002020 B1 EA002020 B1 EA 002020B1 EA 199800746 A EA199800746 A EA 199800746A EA 199800746 A EA199800746 A EA 199800746A EA 002020 B1 EA002020 B1 EA 002020B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- virus
- viruses
- immune response
- attenuated
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 87
- 241001465754 Metazoa Species 0.000 title claims abstract description 27
- 230000002155 anti-virotic effect Effects 0.000 title 1
- 241000700605 Viruses Species 0.000 claims abstract description 358
- 210000004027 cell Anatomy 0.000 claims abstract description 215
- 230000002238 attenuated effect Effects 0.000 claims abstract description 92
- 210000005210 lymphoid organ Anatomy 0.000 claims abstract description 81
- 230000002068 genetic effect Effects 0.000 claims abstract description 70
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 67
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 56
- 230000010076 replication Effects 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 230000014509 gene expression Effects 0.000 claims abstract description 27
- 238000010361 transduction Methods 0.000 claims abstract description 25
- 230000026683 transduction Effects 0.000 claims abstract description 23
- 230000007416 antiviral immune response Effects 0.000 claims abstract description 8
- 239000000427 antigen Substances 0.000 claims description 109
- 108091007433 antigens Proteins 0.000 claims description 109
- 102000036639 antigens Human genes 0.000 claims description 109
- 108010061833 Integrases Proteins 0.000 claims description 59
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 108090000695 Cytokines Proteins 0.000 claims description 40
- 102000004127 Cytokines Human genes 0.000 claims description 36
- 230000002950 deficient Effects 0.000 claims description 35
- 241001430294 unidentified retrovirus Species 0.000 claims description 29
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 16
- 230000010354 integration Effects 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 13
- 208000031886 HIV Infections Diseases 0.000 claims description 10
- 210000004698 lymphocyte Anatomy 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 7
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 5
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 230000005867 T cell response Effects 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 230000007813 immunodeficiency Effects 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 241000701806 Human papillomavirus Species 0.000 claims description 3
- 241000178270 Canarypox virus Species 0.000 claims description 2
- 230000004568 DNA-binding Effects 0.000 claims description 2
- 230000003053 immunization Effects 0.000 abstract description 73
- 238000002649 immunization Methods 0.000 abstract description 73
- 230000003612 virological effect Effects 0.000 abstract description 59
- 239000002245 particle Substances 0.000 abstract description 34
- 230000009385 viral infection Effects 0.000 abstract description 18
- 210000000987 immune system Anatomy 0.000 abstract description 17
- 230000001717 pathogenic effect Effects 0.000 abstract description 17
- 208000036142 Viral infection Diseases 0.000 abstract description 16
- 230000036039 immunity Effects 0.000 abstract description 16
- 230000001681 protective effect Effects 0.000 abstract description 14
- 241000282412 Homo Species 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 10
- 230000005860 defense response to virus Effects 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 description 72
- 108020004414 DNA Proteins 0.000 description 58
- 102100034343 Integrase Human genes 0.000 description 45
- 238000004519 manufacturing process Methods 0.000 description 33
- 241000725303 Human immunodeficiency virus Species 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 238000012217 deletion Methods 0.000 description 21
- 229960005486 vaccine Drugs 0.000 description 21
- 230000037430 deletion Effects 0.000 description 20
- 210000000612 antigen-presenting cell Anatomy 0.000 description 19
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 241000700618 Vaccinia virus Species 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 13
- 230000029812 viral genome replication Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000002458 infectious effect Effects 0.000 description 11
- 230000000735 allogeneic effect Effects 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 210000003071 memory t lymphocyte Anatomy 0.000 description 10
- 230000007918 pathogenicity Effects 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 210000002741 palatine tonsil Anatomy 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 108010067390 Viral Proteins Proteins 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241001529453 unidentified herpesvirus Species 0.000 description 7
- 239000000277 virosome Substances 0.000 description 7
- 241001631646 Papillomaviridae Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 210000003563 lymphoid tissue Anatomy 0.000 description 6
- 229940031626 subunit vaccine Drugs 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 241000700584 Simplexvirus Species 0.000 description 5
- 206010058874 Viraemia Diseases 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 101710205625 Capsid protein p24 Proteins 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 description 4
- 101710177166 Phosphoprotein Proteins 0.000 description 4
- 241001068295 Replication defective viruses Species 0.000 description 4
- 101710149279 Small delta antigen Proteins 0.000 description 4
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 206010064912 Malignant transformation Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000008348 humoral response Effects 0.000 description 3
- 230000037451 immune surveillance Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000001821 langerhans cell Anatomy 0.000 description 3
- 230000036212 malign transformation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004719 natural immunity Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 239000010755 BS 2869 Class G Substances 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010002459 HIV Integrase Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000006215 rectal suppository Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 239000006216 vaginal suppository Substances 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000718541 Tetragastris balsamifera Species 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 208000024697 human cytomegalovirus infection Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108010062490 p27 antigen Proteins 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60462796A | 1996-02-21 | 1996-02-21 | |
| PCT/US1997/002933 WO1997031119A1 (en) | 1996-02-21 | 1997-02-20 | Methods and compositions for protective and therapeutic genetic immunization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA199800746A1 EA199800746A1 (ru) | 1999-02-25 |
| EA002020B1 true EA002020B1 (ru) | 2001-12-24 |
Family
ID=24420371
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA199800746A EA002020B1 (ru) | 1996-02-21 | 1997-02-20 | Способ генерации противовирусного иммунного ответа у человека или животного |
| EA200100302A EA003554B1 (ru) | 1996-02-21 | 1997-02-20 | Фармацевтическая композиция для генерации противовирусного иммунного ответа у человека и животного |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200100302A EA003554B1 (ru) | 1996-02-21 | 1997-02-20 | Фармацевтическая композиция для генерации противовирусного иммунного ответа у человека и животного |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0882134B8 (2) |
| JP (1) | JP2000517290A (2) |
| AP (1) | AP964A (2) |
| AT (1) | ATE429505T1 (2) |
| AU (1) | AU726623B2 (2) |
| CA (1) | CA2246359A1 (2) |
| DE (1) | DE69739372D1 (2) |
| EA (2) | EA002020B1 (2) |
| ES (1) | ES2324745T3 (2) |
| NZ (1) | NZ331369A (2) |
| OA (1) | OA10842A (2) |
| WO (1) | WO1997031119A1 (2) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110898A (en) * | 1996-05-24 | 2000-08-29 | University Of Maryland, Baltimore | DNA vaccines for eliciting a mucosal immune response |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| JP2001516729A (ja) * | 1997-09-15 | 2001-10-02 | ジェネティック・イミューナティ・リミテッド・ライアビリティ・カンパニー | 皮膚の抗原提示細胞に遺伝子を運搬する方法 |
| AU749059B2 (en) * | 1997-12-12 | 2002-06-20 | Cell Genesys, Inc. | Therapeutic use of lentiviral vectors |
| AU6761198A (en) * | 1998-03-17 | 1999-10-11 | Julianna Lisziwiewicz | Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor |
| US6461616B1 (en) * | 2000-09-09 | 2002-10-08 | Akzo Nobel Nv | EIAV p26 deletion vaccine and diagnostic |
| US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| CA2950109C (en) | 2000-10-27 | 2019-02-19 | John W. Hadden | Vaccine immunotherapy for immune suppressed patients |
| US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| PL212047B1 (pl) | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| ES2310201T3 (es) | 2001-02-13 | 2009-01-01 | Government Of The United States Of America, As Represented By The Secretary Of The Army | Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros. |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| NZ536592A (en) | 2002-04-19 | 2007-01-26 | Bavarian Nordic As | Modified vaccinia virus ankara for the vaccination of neonates |
| JP2005537793A (ja) | 2002-09-05 | 2005-12-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法 |
| EP1590432A4 (en) * | 2003-01-15 | 2008-05-14 | Res Inst For Genetic And Human | DNA COMPOSITION AND ITS USE |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| EP1797189A4 (en) * | 2004-09-02 | 2010-05-19 | Qun Chen | ENCAPSIDATION SYSTEM FOR THE PRODUCTION OF RECOMBINANT VIRUSELY PARTICLES |
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| EP2150618B1 (en) | 2007-05-04 | 2017-10-11 | University Health Network | Il-12 immunotherapy for cancer |
| WO2009070639A1 (en) | 2007-11-28 | 2009-06-04 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
| WO2010009465A2 (en) * | 2008-07-18 | 2010-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Htlv-ii vector and methods of use |
| MX2011012147A (es) | 2009-05-15 | 2012-06-19 | Irx Therapeutics Inc | Inmunoterapia de vacuna. |
| CN103097543A (zh) | 2009-12-08 | 2013-05-08 | 伊尔克斯治疗有限公司 | 逆转朗格汉斯细胞免疫抑制的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| AU6816194A (en) * | 1993-04-20 | 1994-11-08 | Robinson, William S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
| US6080408A (en) * | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
-
1997
- 1997-02-20 WO PCT/US1997/002933 patent/WO1997031119A1/en not_active Ceased
- 1997-02-20 AU AU21369/97A patent/AU726623B2/en not_active Ceased
- 1997-02-20 JP JP09530399A patent/JP2000517290A/ja not_active Ceased
- 1997-02-20 NZ NZ331369A patent/NZ331369A/en not_active IP Right Cessation
- 1997-02-20 EA EA199800746A patent/EA002020B1/ru not_active IP Right Cessation
- 1997-02-20 EA EA200100302A patent/EA003554B1/ru not_active IP Right Cessation
- 1997-02-20 CA CA002246359A patent/CA2246359A1/en not_active Abandoned
- 1997-02-20 EP EP97906764A patent/EP0882134B8/en not_active Expired - Lifetime
- 1997-02-20 AT AT97906764T patent/ATE429505T1/de not_active IP Right Cessation
- 1997-02-20 DE DE69739372T patent/DE69739372D1/de not_active Expired - Lifetime
- 1997-02-20 AP APAP/P/1998/001320A patent/AP964A/en active
- 1997-02-20 ES ES97906764T patent/ES2324745T3/es not_active Expired - Lifetime
-
1998
- 1998-08-18 OA OA9800147A patent/OA10842A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0882134B1 (en) | 2009-04-22 |
| DE69739372D1 (de) | 2009-06-04 |
| JP2000517290A (ja) | 2000-12-26 |
| AP9801320A0 (en) | 1998-09-30 |
| EA199800746A1 (ru) | 1999-02-25 |
| CA2246359A1 (en) | 1997-08-28 |
| EP0882134B8 (en) | 2009-09-02 |
| ES2324745T3 (es) | 2009-08-13 |
| EA003554B1 (ru) | 2003-06-26 |
| AU2136997A (en) | 1997-09-10 |
| EA200100302A1 (ru) | 2001-10-22 |
| NZ331369A (en) | 2001-04-27 |
| EP0882134A1 (en) | 1998-12-09 |
| ATE429505T1 (de) | 2009-05-15 |
| OA10842A (en) | 2001-08-14 |
| AP964A (en) | 2001-05-11 |
| AU726623B2 (en) | 2000-11-16 |
| WO1997031119A1 (en) | 1997-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA002020B1 (ru) | Способ генерации противовирусного иммунного ответа у человека или животного | |
| Hanke et al. | Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | |
| Hanke et al. | DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice | |
| Yasutomi et al. | A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge | |
| Sharpe et al. | Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity | |
| JPWO2012053646A1 (ja) | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター | |
| JP2010001290A (ja) | 遺伝子ワクチンのための弱毒化ｖｉｆＤＮＡ免疫化カセット | |
| US8003113B2 (en) | DNA vaccine compositions and methods of use | |
| Agadjanyan et al. | An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV | |
| Flynn et al. | Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination | |
| Radaelli et al. | Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV | |
| Gómez et al. | Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-γ | |
| JP3164351B2 (ja) | 疾患モデルおよびワクチンに使用するプロトタイプＦｅＬＶの分離体 | |
| US8785411B2 (en) | HIV DNA vaccine methods of use | |
| Vanniasinkam et al. | Adenoviral gene delivery for HIV-1 vaccination | |
| Bayer et al. | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes | |
| US20160279229A9 (en) | Viral Vaccine Vectors | |
| Ensoli et al. | Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus | |
| Bolognesi | The immune response to HIV: implications for vaccine development | |
| Ikawait | Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses | |
| Cuisinier et al. | Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection | |
| Aldovini et al. | New AIDS vaccine candidates: antigen delivery and design | |
| AU1971201A (en) | Methods and compositions for protective and therapeutic genetic immunization | |
| JP4914956B2 (ja) | Ｄｎａワクチン | |
| Rollman | Concepts in DNA immunization overcoming viral diversity and enhancing plasmid immunogenicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |